查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球仿製药合同製造市场：市场规模按药物类型、产品、给药途径、应用、地区、竞争战略、细分市场预测至2032
市场调查报告书
商品编码
1182440

全球仿製药合同製造市场：市场规模按药物类型、产品、给药途径、应用、地区、竞争战略、细分市场预测至2032

Generic Pharmaceuticals Contract Manufacturing Market Size- By Drug Type, By Product, By Route of Administration, By Application- Regional Outlook, Competitive Strategies and Segment Forecast to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 244 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

到 2032 年，全球仿製药合同製造市场预计将达到 1214.2 亿美元，复合年增长率为 6.04%。

外包在节省成本和时间方面的优势正在推动行业发展。 治疗慢性病的药物成本高，增加了对具有成本效益的仿製药的需求。 该部门有许多重要的公司，预计将对发展产生重大影响。

本报告考察了全球仿製药合同製造市场，并提供了有关市场动态、市场变量和前景、竞争格局、按药物类型、产品、给药途径、应用和地区、公司概况等进行的市场分析的信息。 .

内容

第一章介绍

  • 调查范围
  • 市场细分分析

第二章研究方法论

  • 调查数据来源
  • 市场规模估计
  • 数据三角测量

第 3 章执行摘要

第四章市场动态

  • 分析驱动因素、制约因素、机遇和挑战
    • 司机
    • 约束因素
    • 机会
    • 任务
  • COVID-19 对全球仿製药合同製造市场的影响

第五章市场变数与展望

  • SWOT 分析
    • 强度
    • 弱点
    • 机会
    • 威胁
  • PESTEL 分析
    • 政治形势
    • 经济状况
    • 社交情况
    • 技术
    • 环境状况
    • 法律状况
  • 波特的五力分析
    • 供应商的议价能力
    • 买家的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争对手之间的敌对关係
  • 热图分析

第六章竞争格局

  • 仿製药全球代工的分销基地、销售区域和产品类型
  • 全球通用合同製造领域的併购、合作伙伴关係、产品发布和协作

第 7 章全球仿製药合同製造市场：按药物类型分类（2019-2032，百万美元）

  • 品牌
  • 没有品牌

第 8 章全球通用合同製造市场：按产品分类（2019-2032，百万美元）

  • API
  • 医药

第 9 章全球通用合同製造市场：按管理途径（2019-2032，百万美元）

  • 口语
  • 肠外
  • 本地
  • 其他

第 10 章全球通用合同製造市场：按应用（2019-2032，百万美元）

  • 抗凝剂
  • 抗糖尿病药
  • 心血管
  • HIV 抗病毒药物
  • 免疫学
  • 神经学
  • 肿瘤学
  • 疼痛
  • 呼吸科
  • 其他

第 11 章全球通用合同製造市场：按地区（2019-2032，百万美元）

  • 市场规模/市场份额：按地区（2019-2025 年）
  • 各地区的市场规模/市场份额（2026 年至 2032 年）
  • 亚太地区
    • 澳大利亚
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 欧洲
    • 法国
    • 德国
    • 意大利
    • 西班牙
    • 英国
    • 其他欧洲
  • 中东和非洲
    • 沙特阿拉伯王国
    • 阿拉伯联合酋长国
    • 其他中东和非洲地区
  • 北美
    • 加拿大
    • 墨西哥
    • 美国
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他拉丁美洲

第12章公司简介

  • Acme Generics Pvt Ltd.
    • 公司简介
    • 财务展望
    • 产品概述
    • 最近的发展
  • Alcami Corp. Inc.
  • Aurobindo Pharma
  • Cambrex Corp.
  • Catalent, Inc
  • Curia Global, Inc.
  • Jubilant Generics Ltd.
  • Metric Contract Services
  • Pfizer CentreOne
  • Recipharm Ab
  • Siegfried Holding AG
  • Syngene International Limited

第13章缩略语列表

第 14 章参考链接

第15章结论

第 16 章范围

简介目录
Product Code: PHAR2215

Global Generic Pharmaceuticals Contract Manufacturing Market Overview:

According to SPER Market Research, the Global Generic Pharmaceuticals Contract Manufacturing Market is estimated to reach USD 121.42 billion by 2032 with a CAGR of 6.04%.

The industry's growth is being driven by the advantages of outsourcing in terms of cost and time savings. A generic medication is a prescription medication that shares the same chemical components as a medication that was first covered by a chemical patent. Following the expiration of the patents on the original medications, generic medications may be sold. Generics function as well in terms of the medical profile because the active chemical component is the same. The active pharmaceutical ingredient (API) in a generic medication is the same as that in the brand-name medication, but there may be differences in the manufacturing method, formulation, excipients, colour, taste, and packaging. Around the world, a sizable population is afflicted with chronic illnesses. For instance, according to the CDC, 6 out of 10 persons in the U.S. have at least one chronic condition, and 4 out of 10 have two or more. Long-term treatment is necessary for chronic diseases. The demand for cost-effective generic drugs for the treatment of chronic diseases is rising as a result of the high cost of pharmaceuticals. It is anticipated that the presence of numerous important firms in this area will have a substantial impact on its development.

Impact of COVID-19 on the Global Generic Pharmaceuticals Contract Manufacturing Market:

This is anticipated to boost the industry's expansion following the pandemic. The regulatory approval process for generic medications has improved. Advancements in this sector are anticipated to benefit the production of generic medications and, as a result, assist the expansion of the sector. The Japanese government is continually working to develop the nation's market for generic medications. The government is also urging medical institutions to promote the use of generic medications and is taking steps to increase the availability of generics in the nation. In the upcoming years, this is anticipated to enhance CMO operations for generic drugs. The amount spent globally on medications is also increasing. The region's growth is further supported by the increasing tendency of pharmaceutical businesses in the area to outsource non-core activities like manufacturing.

Scope of the Report:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Drug Type, By Product, By Route of Administration, By Application
  • Regions covered: Asia Pacific, Europe, Middle East and Africa,North America, Latin America
  • Companies Covered: Acme Generics Pvt Ltd., Alcami Corp. Inc., Aurobindo Pharma, Cambrex Corp., Catalent, Inc, Curia Global, Inc., Jubilant Generics Ltd., Metric Contract Services, Pfizer CentreOne, Recipharm Ab, Siegfried Holding AG, Syngene International Limited

Global Generic Pharmaceuticals Contract Manufacturing Market Segmentation:

  • By Drug Type: Based on the Drug Type, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Branded, Unbranded.
  • By Product: Based on the Product, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; API, Drug Product.
  • By Route of Administration: Based on the Route of Administration, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Oral, Parenteral, Topical, Others.
  • By Application: Based on the Application, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Anticoagulants, Antidiabetic, Cardiovascular, HIV antivirals, Immunology, Neurology, Oncology, Pain, Respiratory, Others.
  • By Region: The lowest CAGR is anticipated in Asia Pacific over the projected period, mostly as a result of the region's inexpensive manufacturing of generic medications.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Generic Pharmaceuticals Contract Manufacturing Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4.Heat map analysis

6. Competitive Landscape

  • 6.1. Global Generic Pharmaceuticals Contract Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Generic Pharmaceuticals Contract Manufacturing

7. Global Generic Pharmaceuticals Contract Manufacturing Market, By Drug Type, 2019-2032 (USD Million)

  • 7.1. Branded
  • 7.2. Unbranded

8. Global Generic Pharmaceuticals Contract Manufacturing Market, By Product, 2019-2032 (USD Million)

  • 8.1. API
  • 8.2. Drug Product

9. Global Generic Pharmaceuticals Contract Manufacturing Market, By Route of Administration, 2019-2032 (USD Million)

  • 9.1. Oral
  • 9.2. Parenteral
  • 9.3. Topical
  • 9.4. Others

10. Global Generic Pharmaceuticals Contract Manufacturing Market, By Application, 2019-2032 (USD Million)

  • 10.1. Anticoagulants
  • 10.2. Antidiabetic
  • 10.3. Cardiovascular
  • 10.4. HIV antivirals
  • 10.5. Immunology
  • 10.6. Neurology
  • 10.7. Oncology
  • 10.8. Pain
  • 10.9. Respiratory
  • 10.10. Others

11. Global Generic Pharmaceuticals Contract Manufacturing Market, By Region, 2019-2032 (USD Million)

  • 11.1. Global Generic Pharmaceuticals Contract Manufacturing Size and Market Share by Region (2019-2025)
  • 11.2. Global Generic Pharmaceuticals Contract Manufacturing Size and Market Share by Region (2026-2032)
  • 11.3. Asia-Pacific
    • 11.3.1. Australia
    • 11.3.2. China
    • 11.3.3. India
    • 11.3.4. Japan
    • 11.3.5. South Korea
    • 11.3.6. Rest of Asia-Pacific
  • 11.4 Europe
    • 11.4.1 France
    • 11.4.2 Germany
    • 11.4.3 Italy
    • 11.4.4 Spain
    • 11.4.5 United Kingdom
    • 11.4.6 Rest of Europe
  • 11.5 Middle East & Africa
    • 11.5.1 Kingdom of Saudi Arabia
    • 11.5.2 United Arab Emirates
    • 11.5.3 Rest of Middle East & Africa
  • 11.6 North America
    • 11.6.1 Canada
    • 11.6.2 Mexico
    • 11.6.3 United States
  • 11.7 Latin America
    • 11.7.1 Argentina
    • 11.7.2 Brazil
    • 11.7.3 Rest of Latin America

12. Company Profiles

  • 12.1 Acme Generics Pvt Ltd.
    • 12.1.1 Company details
    • 12.1.2 Financial outlook
    • 12.1.3 Product summary
    • 12.1.4 Recent developments
  • 12.2 Alcami Corp. Inc.
    • 12.2.1 Company details
    • 12.2.2 Financial outlook
    • 12.2.3 Product summary
    • 12.2.4 Recent developments
  • 12.3 Aurobindo Pharma
    • 12.3.1 Company details
    • 12.3.2 Financial outlook
    • 12.3.3 Product summary
    • 12.3.4 Recent developments
  • 12.4 Cambrex Corp.
    • 12.4.1 Company details
    • 12.4.2 Financial outlook
    • 12.4.3 Product summary
    • 12.4.4 Recent developments
  • 12.5 Catalent, Inc
    • 12.5.1 Company details
    • 12.5.2 Financial outlook
    • 12.5.3 Product summary
    • 12.5.4 Recent developments
  • 12.6 Curia Global, Inc.
    • 12.6.1 Company details
    • 12.6.2 Financial outlook
    • 12.6.3 Product summary
    • 12.6.4 Recent developments
  • 12.7 Jubilant Generics Ltd.
    • 12.7.1 Company details
    • 12.7.2 Financial outlook
    • 12.7.3 Product summary
    • 12.7.4 Recent developments
  • 12.8 Metric Contract Services
    • 12.8.1 Company details
    • 12.8.2 Financial outlook
    • 12.8.3 Product summary
    • 12.8.4 Recent developments
  • 12.9 Pfizer CentreOne
    • 12.9.1 Company details
    • 12.9.2 Financial outlook
    • 12.9.3 Product summary
    • 12.9.4 Recent developments
  • 12.10 Recipharm Ab
    • 12.10.1 Company details
    • 12.10.2 Financial outlook
    • 12.10.3 Product summary
    • 12.10.4 Recent developments
  • 12.11 Siegfried Holding AG
    • 12.11.1 Company details
    • 12.11.2 Financial outlook
    • 12.11.3 Product summary
    • 12.11.4 Recent developments
  • 12.12 Syngene International Limited
    • 12.12.1 Company details
    • 12.12.2 Financial outlook
    • 12.12.3 Product summary
    • 12.12.4 Recent developments

13. List of Abbreviations

14. Reference Links

15. Conclusion

16. Research Scope